The prevalence of chronic myeloid leukaemia is steadily rising due to the substantial prolongation of survival that has been achieved with targeted therapy. These updated guidelines on chronic myeloid leukaemia...
Background: Dasatinib, a potent Bcr?Abl tyrosine kinase inhibitor, is approved for the treatment of chronic?phase chronic myeloid leukemia (CML-CP) in the frontline and salvage settings. Notable side effects include pleural...
Cepheid announced that it has received clearance from the FDA for Xpert BCR-ABL Ultra for monitoring disease burden in patients...
The FDA has approved an update to the product labelling of Sprycel (dasatinib), from BMS/Otsuka. The labeling now includes five-year...
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
ARIAD Pharmaceuticals announced that the FDA has granted Iclusig (ponatinib) full approval for the treatment of adult patients with chronic...
New Novartis data from two long-term Treatment-free Remission (TFR) studies of Tasigna (nilotinib) in patients with Philadelphia chromosome-positive (Ph+) chronic...
Acute myeloid leukemia (AML) is a malignant disease characterized by abnormal growth and differentiation of hematopoietic stem cells.
Bosutinib is a second-generation tyrosine kinase inhibitor (2GTKI) approved at 400 mg once daily (QD) as first-line therapy in patients with chronic myeloid leukemia (CML) patients and at 500 mg QD in patients who are resistant...
The aim of this study was to assess the efficacy and safety of a lower dose of dasatinib (50 mg daily) in patients with newly diagnosed CML-CP.